Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Rheumatology International
Published in: Rheumatology International 8/2014

01-08-2014 | Letter to the Editor

Future directions for the investigation of intranasal oxytocin and pain

Comment on: Oxytocin nasal spray in fibromyalgic patients (Rheumatol Int. E-pub ahead of print. doi: 10.1007/s00296-014-2953-y)

Authors: Joshua A. Rash, Tavis S. Campbell

Published in: Rheumatology International | Issue 8/2014

Login to get access

Excerpt

It is with great interest that we read the article “Oxytocin nasal spray in fibromyalgic patients” published in Rheumatology International. Mameli et al. [1] conducted a placebo-controlled, double-blind crossover trial and reported that daily administration of 80 IU intranasal oxytocin over the course of 3 weeks did not result in adverse side effects or lower reports of pain among 14 women with fibromyalgia. We commend the authors for conducting an innovative trial using daily intranasal oxytocin administration. Several points can be advanced from this article to improve future trials assessing oxytocin and pain associations. …
Literature
1.
Mameli S, Pisanu G, Sardo S, Marchi A, Pili A, Carboni M, Minerba L, Trincas G, Carta M, Melis M (2014) Oxytocin nasal spray in fibromyalgic patients. Rheumatol Int, pp 1–6
2.
Kessner S, Sprenger C, Wrobel N, Wiech K, Bingel U (2013) Effect of oxytocin on placebo analgesia: a randomized study. JAMA 310(16):1733–1735PubMedCrossRef
3.
Rash JA, Aguirre-Camacho A, Campbell TS (2014) Oxytocin and pain: a systematic review and synthesis of findings. Clin J Pain 30(5):453-462
4.
Cardoso C, Ellenbogen MA, Orlando MA, Bacon SL, Joober R (2013) Intranasal oxytocin attenuates the cortisol response to physical stress: a dose–response study. Psychoneuroendocrinology 38(3):399–407PubMedCrossRef
5.
Van IJzendoorn MH, Bhandari R, Van der Veen R, Grewen KM, Bakermans-Kranenburg MJ (2012) Elevated salivary levels of oxytocin persist more than 7 h after intranasal administration. Front Neurosci 6:174
6.
Faul F, Erdfelder E, Lang A-G, Buchner A (2007) G* Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods 39(2):175–191PubMedCrossRef
7.
Rash JA, Campbell TS (Accepted [Ref# PM-PSY13-531]) The effect of intranasal oxytocin administration on acute cold pressor pain: a placebo-controlled, double-blind, within-subjects crossover investigation. Psychosom Med
8.
MacDonald E, Dadds MR, Brennan JL, Williams K, Levy F, Cauchi AJ (2011) A review of safety, side-effects and subjective reactions to intranasal oxytocin in human research. Psychoneuroendocrinology 36(8):1114–1126PubMedCrossRef
Metadata
Title
Future directions for the investigation of intranasal oxytocin and pain
Comment on: Oxytocin nasal spray in fibromyalgic patients (Rheumatol Int. E-pub ahead of print. doi: 10.1007/s00296-014-2953-y)
Authors
Joshua A. Rash
Tavis S. Campbell
Publication date
01-08-2014
Publisher
Springer Berlin Heidelberg
Published in
Rheumatology International / Issue 8/2014
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-014-3070-7

Other articles of this Issue 8/2014

Rheumatology International 8/2014 Go to the issue

Original Article

HLA-DRB1 and HLA-DQB1 allele associations in an Albanian patient population with rheumatoid arthritis: correlations with the specific autoantibody markers and inter-population DRB1 allele frequency variability

Short Communication

Involvement of BDNF in knee osteoarthritis: the relationship with inflammation and clinical parameters

Short Communication

Carotid intima-media thickness in children with Kawasaki disease

Short Communication

Non-systemic juvenile idiopathic arthritis outcome after reaching clinical remission with anti-TNF-α therapy: a clinical practice observational study of patients who discontinued treatment

Letter to the Editor

Interleukin-15 and its receptor (IL-15Rα) serve as new therapeutic implications for Behçet’s disease

Short Communication

Serum resistin levels: a possible correlation with pulmonary vascular involvement in patients with systemic sclerosis
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits